Antifungal combination therapy

Details Antifungal combination therapy Antifungal combination therapy

A - Human Necessities

61

K

A61K 38/12 (2006.01) A61K 38/17 (2006.01) A61K 45/06 (2006.01)

Patent

CA 2265824

There is described antifungal combination therapy comprising the use of known antifungal agents such as the azoles or polyenes in combination with a pneumocandin derivative antifungal agent. More particularly, the invention relates to antifungal combination therapy comprising the use of azoles such as fluconazole, voriconazole, itraconazole, ketoconazole, miconazole, ER 30346, SCH 56592;polyenes such as amphotericin B nystatin or liposomal and lipid forms thereof such as Abelcet, AmBisome and Amphocil; purine or pyrimidine nucleotide inhibitors such as flucytosine; or polyoxins such as nikkomycins, in particular nikkomycin Z or other chitin inhibitors, elongation factor inhibitors such as sordarin and analogs thereof, mannan inhibitors such as predamycin, bactericidal/permeability-inducing (BPI) protein products such as XMP.97 or XMP.127 or complex carbohydrate antifungal agents such as CAN-296 in combination with a pneumocandin derivative as described herein.

On décrit une thérapie antifongique combinée qui consiste à utiliser des agents antifongiques connus tels que les azoles ou les polyènes en combinaison avec un agent antifongique à base de dérivé de la pneumocandine. D'une manière plus spécifique cette invention concerne une thérapie antifongique combinée qui consiste en l'utilisation d'azoles tels que le fluconazole, le voriconazole, l'itraconazole, le cétoconazole, le miconazole, ER 30346, SCH 56592; de polyènes tels que l'amphotéricine B, la nystatine ou leurs formes liposomale et lipidique telles que l'Abelcet, l'Ambisome et l'Amphocil; des inhibiteurs nucléotidiques de purine ou de pyrimidine tels que la flucytosine; ou des polyoxines telles que les nikkomycines, plus particulièrement la nikkomycine Z ou d'autres inhibiteurs de chitine, des inhibiteurs du facteur d'élongation tels que la sordarine et des analogues de cette dernière, des inhibiteurs de mannane tels que la prédamycine, des produits protéiques bactéricides/induisant la perméabilité (BIP) tels que le XMP.97 ou le XMP.127 ou bien des agents antifongiques à hydrates de carbone complexes tels que le CAN-296 en combinaison avec un dérivé de pneumocandine comme celui décrit ci-avant.

Affiliated with

Also associated with

Rating

Antifungal combination therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antifungal combination therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antifungal combination therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2043267